Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
复制标题
埃克替尼单药或联合贝伐珠单抗一线治疗中国 EGFR 突变激活的晚期非鳞状非小细胞肺癌患者：一项回顾性研究
DOI：
10.1111/1759-7714.14079
复制
发表时间：
2021-09
期刊：
影响因子：
2.9
通讯作者：
Pan Z
中科院分区：
文献类型：
--
作者：
Jiang Z;Zhang J;Sun H;Wang C;Zhang Y;Li Y;Pan Z
本研究重点比较埃克替尼单药治疗和埃克替尼加贝伐珠单抗联合治疗携带EGFR突变的非小细胞肺癌（NSCLC）病例的安全性和治疗效果。回顾性收集了2018年10月至2019年12月期间天津医科大学附属肿瘤医院肿瘤研究所的数据，其中携带EGFR突变的NSCLC病例在贝伐珠单抗联合或不联合的情况下接受了埃克替尼一线治疗。本研究纳入90例病例，其中埃克替尼组（I）60例，埃克替尼+贝伐珠单抗组（IB）30例。我们研究中评估中位PFS的随访期为18个月。埃克替尼联合贝伐珠单抗组的中位PFS为18.0个月（95%置信区间[CI]：14.7-21.3），埃克替尼单药组为11个月（95% CI：8.9-13.1）（风险比0.54，95% CI：0.31-0.92; p = 0.029）。根据基于EGFR基因组畸变类型的亚组分析，与I组相比，在IB组中携带21号外显子点突变（Ex21.L858R）的病例中观察到中位PFS延长（未达到vs. 11个月[8.8-13.2]，p = 0.021）。然而，EGFR基因19号外显子缺失的病例之间的差异并不显著。两组之间的DCR和ORR相当。与埃克替尼单药治疗组相比，联合治疗组观察到高血压和蛋白尿的发生率显著更高。这是第一项提供埃克替尼联合贝伐珠单抗一线治疗携带EGFR突变的晚期NSCLC病例获益的进一步证据的研究。然而，这些发现需要通过前瞻性3期临床研究进行验证。90例患者入组研究。埃克替尼联合贝伐珠单抗组的中位PFS为18.0个月（95% CI：14.7-21.3），埃克替尼单药组为11个月（95% CI：8.9-13.1）（风险比0.54，95% CI：0.31-0.92; p = 0.029）。根据基于EGFR基因组畸变类型的亚组分析，与埃克替尼组相比，在合并组中携带21号外显子点突变（Ex21.L858R）的病例中观察到中位PFS延长（未达到vs. 11个月，p = 0.021）。
This study focused on comparing the safety and therapeutic effects between icotinib monotherapy and icotinib plus bevacizumab combined therapy in non‐small cell lung cancer (NSCLC) cases harboring EGFR mutations. Data were collected retrospectively from the Cancer Institute and Hospital of Tianjin Medical University between October 2018 and December 2019, where the NSCLC cases that harbored EGFR mutations underwent first‐line therapy with icotinib in the presence or absence of bevacizumab. This study included 90 cases, of which 60 patients were in the icotinib group (I) and 30 in the icotinib plus bevacizumab group (IB). The follow‐up period to evaluate median PFS in our study was 18 months. Median PFS was 18.0 months (95% confidence interval [CI]: 14.7–21.3) with icotinib plus bevacizumab and 11 months (95% CI: 8.9–13.1) with icotinib alone (hazard ratio 0·54, 95% CI: 0.31–0.92; p = 0.029). According to the subgroup analyses based on the type of EGFR genomic aberration, a prolonged median PFS was observed in the cases harboring exon 21 point mutation (Ex21.L858R) in the IB group compared to the I group (not reached vs. 11 months [8.8–13.2], p = 0.021). However, the difference between the cases harboring exon 19 deletions in the EGFR gene was not significant. The DCR and ORR were comparable between both groups. Substantially higher incidences of hypertension and proteinuria were observed in the combined group compared to the icotinib monotherapy group. This is the first study to provide further evidence of the benefits of applying icotinib in combination with bevacizumab as first‐line treatment for advanced NSCLC cases harboring EGFR mutations. However, these findings need to be verified through prospective phase 3 clinical studies. Ninety patients were enrolled in the study. Median PFS was 18.0 months (95% CI: 14.7–21.3) with icotinib plus bevacizumab and 11 months (95% CI: 8.9–13.1) with icotinib alone (hazard ratio 0·54, 95% CI: 0.31–0.92; p = 0.029). According to the subgroup analyses based on the type of EGFR genomic aberration, a prolonged median PFS was observed in the cases harboring exon 21 point mutation (Ex21.L858R) in the combined compared to the icotinib group (not reached vs. 11 months, p = 0.021).
登录
查看更多内容
影响因子：
76.2
作者：
Rosell, Rafael;Dafni, Urania;Stahel, Rolf A.
通讯作者：
Stahel, Rolf A.
影响因子：
158.5
作者：
Soria, J. -C.;Ohe, Y.;Nguyen, Nhung
通讯作者：
Nguyen, Nhung
影响因子：
5.3
作者：
Zeng, Liang;Xiao, Lili;Mansfield, Aaron S.
通讯作者：
Mansfield, Aaron S.
影响因子：
50.5
作者：
Mayo-de-las-Casas, C.;Jordana-Ariza, N.;Molina-Vila, M. A.
通讯作者：
Molina-Vila, M. A.
亚洲晚期非小细胞腺癌组织学肺癌患者 EGFR 突变的前瞻性分子流行病学研究 (PIONEER)。
DOI：
10.1097/jto.0000000000000033
发表时间：
2014-02
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Shi Y;Au JS;Thongprasert S;Srinivasan S;Tsai CM;Khoa MT;Heeroma K;Itoh Y;Cornelio G;Yang PC
通讯作者：
Yang PC